Vanguard Group Inc Denali Therapeutics Inc. Transaction History
Vanguard Group Inc
- $5.37 Trillion
- Q1 2025
A detailed history of Vanguard Group Inc transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 11,799,757 shares of DNLI stock, worth $173 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11,799,757
Previous 12,021,230
1.84%
Holding current value
$173 Million
Previous $245 Million
34.5%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding DNLI
# of Institutions
236Shares Held
127MCall Options Held
37.3KPut Options Held
7.9K-
Black Rock Inc. New York, NY13.2MShares$194 Million0.01% of portfolio
-
Baillie Gifford & CO12.1MShares$178 Million0.15% of portfolio
-
Wellington Management Group LLP Boston, MA11.4MShares$168 Million0.03% of portfolio
-
Ubs Asset Management Americas Inc Chicago, IL6.77MShares$99.4 Million0.02% of portfolio
-
Temasek Holdings (Private) LTD Singapore, U05.36MShares$78.7 Million0.37% of portfolio
About Denali Therapeutics Inc.
- Ticker DNLI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 134,174,000
- Market Cap $1.97B
- Description
- Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...